Urogen Pharma Ltd.(URGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

URGN Urogen Pharma Ltd.

Trading 11-05 11:28:09 EST

27.21

-1.53

-5.32%

High28.42	Low26.27	Vol791.83K
Open28.05	D1 Closing28.74	Amplitude7.48%
Mkt Cap1.32B	Tradable Cap1.18B	Total Shares48.68M
T/O21.28M	T/O Rate1.83%	Tradable Shares43.35M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"URGN","market":"US","secType":"STK","nameCN":"Urogen Pharma Ltd.","latestPrice":27.21,"timestamp":1793896088770,"preClose":28.74,"halted":0,"volume":791834,"delay":0,"changeRate":-0.05323590814196234,"floatShares":43353800,"shares":48682280,"eps":-1.97,"marketStatus":"Trading","change":-1.53,"latestTime":"11-05 11:28:09 EST","open":28.05,"high":28.42,"low":26.27,"amount":21282795.4769,"amplitude":0.074809,"askPrice":27.28,"askSize":2,"bidPrice":27.03,"bidSize":19,"shortable":0,"etf":0,"ttmEps":-1.97,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1793912400000},"marketStatusCode":2,"adr":0,"adrRate":0,"listingDate":1493870400000,"exchange":"NASDAQ","adjPreClose":28.74,"preHourTrading":{"tag":"盘前","latestPrice":28.48,"preClose":28.74,"latestTime":"09:29 EST","volume":4082,"amount":116139.684284,"timestamp":1793888999999,"change":-0.26,"changeRate":-0.009047,"amplitude":0.0508},"postHourTrading":{"tag":"盘后","latestPrice":28.72,"preClose":28.74,"latestTime":"19:30 EST","volume":19159,"amount":550628.0812,"timestamp":1793838603708,"change":-0.02,"changeRate":-0.000696,"amplitude":0.000696},"volumeRatio":1.477634,"impliedVol":0.5175,"impliedVolPercentile":0.0359},"requestUrl":"/m/hq/s/URGN/tweets","defaultTab":"tweets","newsList":[{"id":"2681755470","title":"Analysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN), Alnylam Pharma (ALNY) and ACADIA Pharmaceuticals (ACAD)","url":"https://stock-news.laohu8.com/highlight/detail?id=2681755470","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681755470?lang=en_us&edition=fundamental","pubTime":"2026-11-05 21:20","pubTimestamp":1793884827,"startTime":"0","endTime":"0","summary":"Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Urogen Pharma (URGN), Alnylam Pharma (ALNY) and AC...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-urogen-pharma-urgn-alnylam-pharma-alny-and-acadia-pharmaceuticals-acad-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-urogen-pharma-urgn-alnylam-pharma-alny-and-acadia-pharmaceuticals-acad-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4581","LU2065170008.USD","LU0109394709.USD","LU0128526141.USD","BK4548","ALNY","LU0320765992.SGD","URGN","GNMX","LU0882574055.USD","XBI","LU2065171311.SGD","LU2065171402.SGD","BK4137","XLV","LABU","LU0114720955.EUR","BK4585","LU2065169927.USD","LU0029874061.USD","BK4588","BK4139","PBE","HCSG","LU0889565916.HKD","ACAD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2681939920","title":"US Physical Therapy Inc Q3 Revenue Rises 13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2681939920","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2681939920?lang=en_us&edition=fundamental","pubTime":"2026-11-05 05:35","pubTimestamp":1793828126,"startTime":"0","endTime":"0","summary":"US Physical Therapy Inc Q3 revenue rises 13%OverviewUS outpatient therapy operator's Q3 revenue rose 13% yr/yrAdjusted EPS for Q3 beat analyst expectationsCompany's results boosted by integration of 7","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L1JU:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","USPH","LFSC","LIVN","LU0012050646.USD","LU2065171311.SGD","LU2065171402.SGD","URGN","BK4185","LU2065170008.USD","LU0106261612.USD","LU2065169927.USD","BK4082"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680134063","title":"UroGen Pharma Down over 14%, on Track for Largest Percent Decrease Since December 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2680134063","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680134063?lang=en_us&edition=fundamental","pubTime":"2026-11-04 23:45","pubTimestamp":1793807100,"startTime":"0","endTime":"0","summary":"UroGen Pharma Ltd.  is currently at $29.51, down $4.89 or 14.22%--Would be lowest close since June 11, 2026, when it closed at $29.50--On pace for largest percent decrease since Dec. 2, 2025, when it fell 14.34%--Snaps a two day winning streak--Up 26% year-to-date--Down 54.83% from its all-time closing high of $65.33 on May 18, 2018--Up 52.82% from 52 weeks ago , when it closed at $19.31--Down 41.32% from its 52-week closing high of $50.29 on Aug. 19, 2026--Up 73.59% from its 52-week closing low of $17.00 on March 30, 2026--Traded as low as $27.55; lowest intraday level since June 9, 2026, when it hit $26.60--Down 19.91% at today's intraday low; largest intraday percent decrease since May 21, 2025, when it fell as much as 54.64%All data as of 10:42:37 AM ETSource: Dow Jones Market Data, FactSet","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","URGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680050936","title":"UroGen Pharma Ltd. Reports Results for the Quarter Ended September 30 - Earnings Summary","url":"https://stock-news.laohu8.com/highlight/detail?id=2680050936","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680050936?lang=en_us&edition=fundamental","pubTime":"2026-11-04 22:31","pubTimestamp":1793802714,"startTime":"0","endTime":"0","summary":"UroGen Pharma Ltd. reports results for the quarter ended September 30 - Earnings SummaryUroGen Pharma Ltd.URGN.OQreported a quarterly adjusted loss of 3 cents per share for the quarter ended September","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL5N46L24Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","URGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680905179","title":"UroGen Pharma Q3 EPS $(0.03) Misses $0.14 Estimate, Sales $89.001M Miss $89.918M Estimate","url":"https://stock-news.laohu8.com/highlight/detail?id=2680905179","media":"Benzinga Earnings","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680905179?lang=en_us&edition=fundamental","pubTime":"2026-11-04 21:10","pubTimestamp":1793797851,"startTime":"0","endTime":"0","summary":"UroGen Pharma (NASDAQ:URGN) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $0.14 by 121.43 percent. This is a 95.65 percent increase over losses of $(0.69) per share from","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"11c8fbbf839f433c9d274cef5f173382","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/11/62862206/urogen-pharma-q3-eps-0-03-misses-0-14-estimate-sales-89-001m-miss-89-918m-estimate","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["URGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680512440","title":"UroGen Pharma Q3 Revenue Misses Expectations on Jelmyto Decline","url":"https://stock-news.laohu8.com/highlight/detail?id=2680512440","media":"Reuters","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680512440?lang=en_us&edition=fundamental","pubTime":"2026-11-04 21:09","pubTimestamp":1793797767,"startTime":"0","endTime":"0","summary":"UroGen Pharma Q3 revenue misses expectations on JELMYTO declineOverviewUS biotechnology firm's Q3 revenue rose yr/yr but missed analyst expectationsQ3 net loss narrowed yr/yr but missed analyst expect","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nL2N46L0R4:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2362541513.USD","LU0079474960.USD","LU1585245621.USD","LU2362540622.SGD","IE00B4R5TH58.HKD","IE00B19Z9Z06.USD","LU2462157665.USD","IE00BJT1NW94.SGD","IE0002270589.USD","IE0009355771.USD","IE00B19Z3B42.SGD","LU2236285917.USD","SG9999001176.USD","MIRM","SG9999001176.SGD","LU0061475181.USD","IE00BFTCPJ56.SGD","LU0256863811.USD","LU2324357040.USD","LU0289739699.SGD","LU0320765992.SGD","BK4585","URGN","LU1093756168.USD","IE00B19Z9P08.USD","IBB","IE00B19Z3581.USD","LU1093756325.SGD","LU2456880835.USD","LU1430594728.SGD","IBBQ","VRTX","GNMX","BBH","IE00B2B36J28.USD","LU0058720904.USD","BK4139","IE00BZ9MQY76.HKD","LU1778281490.HKD","IDNA","BK4567","LU1674673428.USD","SGXZ57979304.SGD","BIB","IE00B894F039.SGD","SG9999013999.USD","TBXU","PBE","LU2362541273.HKD","LU2468319806.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680051969","title":"UroGen Q3 2026 Net Loss Narrows 96% Year over Year to $1.46 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2680051969","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680051969?lang=en_us&edition=fundamental","pubTime":"2026-11-04 21:04","pubTimestamp":1793797459,"startTime":"0","endTime":"0","summary":"UroGen Q3 2026 net loss narrows 96% year over year to $1.46 millionUroGen Pharma’s third-quarter 2026 net loss narrowed 96% year over year to $1.46 million.Revenue more than tripled year over year to ","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261104:nNDL4dcdtV:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00B3QW5Z07.USD","LU2095319765.USD","SG9999014021.USD","SG9999014039.USD","NDAQ","BK4588","IE00BQXX3D17.EUR","LU0314104364.USD","IE00BN0W2W23.USD","LU2210149790.SGD","IE00BGHQF748.EUR","SG9999014013.SGD","BCDF","IE00BQXX3C00.GBP","URGN","IE00BN0W2T93.GBP","BK4112","IE00BKPKM429.USD","LU2210150020.SGD","BK4139","IE00BQXX3F31.USD","IE00BN0W2V16.EUR","BK4585","IE00B64PRP62.GBP","SG9999014005.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680757276","title":"UroGen Doses First Patient in Phase 1 Trial of UGN-501 for Bladder Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2680757276","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2680757276?lang=en_us&edition=fundamental","pubTime":"2026-11-02 21:09","pubTimestamp":1793624972,"startTime":"0","endTime":"0","summary":"UroGen Doses First Patient in Phase 1 Trial of UGN-501 for Bladder CancerUroGen Pharma dosed the first patient in a Phase 1 trial of UGN-501, an investigational oncolytic virus for recurrent non-muscl","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261102:nNDLQnqmJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BN0W2V16.EUR","SG9999014021.USD","BK4588","LU2210150020.SGD","IE00BQXX3F31.USD","IE00B64PRP62.GBP","SG9999014039.USD","IE00B3QW5Z07.USD","IE00BGHQF748.EUR","BK4112","LU2210149790.SGD","IE00BQXX3D17.EUR","BK4585","SG9999014005.SGD","LU2095319765.USD","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","SG9999014013.SGD","BK4139","BCDF","IE00BN0W2W23.USD","IE00BKPKM429.USD","NDAQ","URGN","LU0314104364.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1115262422","title":"Earning Preview: Urogen Pharma Ltd. this quarter’s revenue is expected to increase by 173.72%, and institutional views are mostly bullish","url":"https://stock-news.laohu8.com/highlight/detail?id=1115262422","media":"Earnings Agent","labels":["earningPreview"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1115262422?lang=en_us&edition=fundamental","pubTime":"2026-10-29 00:54","pubTimestamp":1793206475,"startTime":"0","endTime":"0","summary":"Abstract Urogen Pharma Ltd. will report quarterly results on November 4, 2026 Pre-MKt; investors are watching whether accelerating product uptake and operating leverage can translate into positive...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":"Earning Preview: Urogen Pharma Ltd. this quarter’s revenue is expected to increase by 173.72%, and institutional views are mostly bullish","news_tag":"earningPreview","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["URGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679249796","title":"UroGen's Zusduri Offers Early Innings Opportunity, Oppenheimer Says","url":"https://stock-news.laohu8.com/highlight/detail?id=2679249796","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2679249796?lang=en_us&edition=fundamental","pubTime":"2026-10-29 00:38","pubTimestamp":1793205532,"startTime":"0","endTime":"0","summary":"UroGen Pharma  is expected to benefit from the commercial opportunity of its Zusduri bladder cancer treatment, Oppenheimer said in a note Wednesday after hosting roadshow meetings in Denver and Los Angeles last week.\"We believe the patient and provider incentives favoring Zusduri over surgery remain underappreciated,\" the report said.The note pointed to potential for inflection next year off planned direct-to-consumer marketing while the company expects linear quarterly growth through 2026.The report said launch momentum should more than offset any seasonal headwind from lighter Q3 procedure volumes.With fewer than 10% of some 6,500 targeted physicians having tried the product, early adopters poised to broaden use, raising confidence in 2030 peak sales forecast of $1.2 billion, it said.Oppenheimer kept its outperform rating and a $60 price target.Price: 33.56, Change: -0.35, Percent Change: -1.03","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["URGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678849364","title":"Analysts Offer Insights on Healthcare Companies: HCA Healthcare (HCA) and Urogen Pharma (URGN)","url":"https://stock-news.laohu8.com/highlight/detail?id=2678849364","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678849364?lang=en_us&edition=fundamental","pubTime":"2026-10-28 20:50","pubTimestamp":1793191845,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on HCA Healthcare (HCA) and Urogen Pharma (URGN) with b...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-hca-healthcare-hca-and-urogen-pharma-urgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-hca-healthcare-hca-and-urogen-pharma-urgn-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LU0203345920.USD","LU1261432733.SGD","LU0203347892.USD","SG9999014005.SGD","LU0029864427.USD","LU1267930573.SGD","XLV","LU0708994859.HKD","BK4588","BK4185","LU0433182093.SGD","LU0310800379.SGD","LU1150488218.USD","LU2244417387.USD","IE00B3S45H60.SGD","LABU","LU0648001328.SGD","LU0211327993.USD","LU1119994496.HKD","LU0980610538.SGD","LU1267930490.SGD","LU0068578508.USD","LU2355687059.USD","LU1150488135.SGD","LU0882574055.USD","HCA","IHF","LU0128525929.USD","LU0985489474.SGD","SG9999014013.SGD","BK4585","LU0310799852.SGD","SG9999014021.USD","LU0187121727.USD","BK4139","LU1084165304.USD","BK4581","IE00B775SV38.USD","LU0211328371.USD","SG9999014039.USD","XBI","LU0868494617.USD","LU0114720955.EUR","URGN","LU0130102774.USD","LU1489326972.SGD","LU1201861249.SGD","BK4504","LU0878866978.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678013462","title":"UroGen’s Jelmyto Shows 47.8-Month Median Response Duration in Olympus Study Follow-up","url":"https://stock-news.laohu8.com/highlight/detail?id=2678013462","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678013462?lang=en_us&edition=fundamental","pubTime":"2026-10-28 20:03","pubTimestamp":1793189014,"startTime":"0","endTime":"0","summary":"UroGen’s JELMYTO Shows 47.8-Month Median Response Duration in Olympus Study Follow-UpUroGen Pharma announced publication of final five-year Olympus follow-up results for Jelmyto on Oct. 28, 2026.Resul","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261028:nNDLyLTRg:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3D17.EUR","URGN","IE00BN0W2V16.EUR","IE00BQXX3F31.USD","LU2210150020.SGD","LU2095319765.USD","IE00BN0W2W23.USD","IE00BN0W2T93.GBP","IE00BQXX3C00.GBP","BK4588","SG9999014005.SGD","IE00B64PRP62.GBP","IE00BKPKM429.USD","BK4139","IE00BGHQF748.EUR","BK4585","SG9999014039.USD","SG9999014021.USD","BK4112","LU0314104364.USD","LU2210149790.SGD","NDAQ","BCDF","SG9999014013.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678817024","title":"UroGen Pharma Sets Third-Quarter Financial Results Release","url":"https://stock-news.laohu8.com/highlight/detail?id=2678817024","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2678817024?lang=en_us&edition=fundamental","pubTime":"2026-10-28 06:00","pubTimestamp":1793138426,"startTime":"0","endTime":"0","summary":"UroGen Pharma Sets Third-Quarter Financial Results ReleaseUroGen Pharma will report third-quarter 2026 financial results on Nov. 4, 2026, before the stock market opens.A live earnings webcast and conf","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261027:nNDL7n0LqF:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE00BQXX3D17.EUR","IE00BKPKM429.USD","IE00BN0W2T93.GBP","LU2095319765.USD","IE00BQXX3F31.USD","LU0314104364.USD","BCDF","LU2210150020.SGD","IE00BGHQF748.EUR","BK4588","SG9999014039.USD","BK4139","BK4585","BK4112","SG9999014013.SGD","URGN","NDAQ","IE00BQXX3C00.GBP","LU2210149790.SGD","IE00B64PRP62.GBP","IE00BN0W2W23.USD","SG9999014021.USD","IE00BN0W2V16.EUR","SG9999014005.SGD","IE00B3QW5Z07.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676697570","title":"UroGen Pharma (URGN) Wins FDA Filing Acceptance, Is The Stock Still Cheap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2676697570","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676697570?lang=en_us&edition=fundamental","pubTime":"2026-10-20 23:37","pubTimestamp":1792510658,"startTime":"0","endTime":"0","summary":"UroGen Pharma (URGN) just had a clear catalyst. The FDA accepted its New Drug Application for UGN-103, an investigational bladder cancer treatment, and set a Prescription Drug User Fee Act decision date of June 14, 2027.\nUroGen Pharma’s share price tells a mixed story. The stock has pulled back sharply in the short term, with the share price down 21.0% over 30 days and 22.0% over 90 days, yet year to date it is still up 50.4% and the 1-year total shareholder return is 89.8%. Over three years,...","market":"sg","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","type":0,"news_type":0,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-urgn/urogen-pharma/news/urogen-pharma-urgn-wins-fda-filing-acceptance-is-the-stock-s","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-urgn/urogen-pharma/news/urogen-pharma-urgn-wins-fda-filing-acceptance-is-the-stock-s","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4139","URGN","BK4588","LABU","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676687934","title":"Analysts Offer Insights on Healthcare Companies: Urogen Pharma (URGN), Genmab (GMAB) and Neogen (NEOG)","url":"https://stock-news.laohu8.com/highlight/detail?id=2676687934","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676687934?lang=en_us&edition=fundamental","pubTime":"2026-10-20 00:00","pubTimestamp":1792425657,"startTime":"0","endTime":"0","summary":"There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Urogen Pharma (URGN), Genmab (GMAB) and Neogen (NEOG...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-urogen-pharma-urgn-genmab-gmab-and-neogen-neog-blurbs-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/analysts-offer-insights-on-healthcare-companies-urogen-pharma-urgn-genmab-gmab-and-neogen-neog-blurbs-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4137","BK4198","HCSG","NEOG","XLV","LU2211817866.USD","BK4588","BK4139","LU0029874061.USD","LU0128526141.USD","BK4581","LABU","URGN","XBI","BK4585","GMAB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676668422","title":"UroGen Pharma Price Target Maintained with a $75.00/Share by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2676668422","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676668422?lang=en_us&edition=fundamental","pubTime":"2026-10-19 22:41","pubTimestamp":1792420860,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/URGN/analyst-ratings","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["URGN","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2676683099","title":"FDA Accepts UroGen's UGN-103 Application for Bladder Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2676683099","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2676683099?lang=en_us&edition=fundamental","pubTime":"2026-10-19 20:03","pubTimestamp":1792411401,"startTime":"0","endTime":"0","summary":"FDA Accepts UroGen's UGN-103 Application for Bladder Cancer TreatmentFDA accepted UroGen Pharma’s UGN-103 application to treat adults with recurrent low-grade intermediate-risk non-muscle-invasive bla","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20261019:nNDLgQ8bN:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SG9999014013.SGD","BK4588","LU2210149790.SGD","IE00BQXX3C00.GBP","IE00BN0W2T93.GBP","SG9999014021.USD","BK4112","BK4585","IE00B64PRP62.GBP","IE00BKPKM429.USD","SG9999014039.USD","IE00BN0W2V16.EUR","IE00BGHQF748.EUR","LU0314104364.USD","LU2210150020.SGD","IE00BN0W2W23.USD","SG9999014005.SGD","IE00BQXX3F31.USD","NDAQ","LU2095319765.USD","BCDF","BK4139","URGN","IE00B3QW5Z07.USD","IE00BQXX3D17.EUR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2674009148","title":"UroGen Pharma falls -12.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2674009148","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2674009148?lang=en_us&edition=fundamental","pubTime":"2026-10-09 00:05","pubTimestamp":1791475541,"startTime":"0","endTime":"0","summary":"UroGen Pharma (URGN) is down -12.8%, or -$5.20 to $35.50. Published first on TheFly – the ultimate source for real-time, market-moving breaking fin...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/urogen-pharma-falls-12-8-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/urogen-pharma-falls-12-8-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","URGN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666253912","title":"Tyra Biosciences Stock Plunges 22% as Bladder Cancer Pill Fails to Impress","url":"https://stock-news.laohu8.com/highlight/detail?id=2666253912","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666253912?lang=en_us&edition=fundamental","pubTime":"2026-09-09 22:44","pubTimestamp":1788965040,"startTime":"0","endTime":"0","summary":"Tyra Biosciences is taking on Johnson & Johnson to develop a next-generation treatment common type of bladder cancer, but the latest data for its experimental pill failed to inspire confidence.The Pha","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IE0009355771.USD","LU0426417589.USD","IE00BLSP4239.USD","BMED","LU1032466523.USD","LU1244550577.SGD","FHLC","IE000F7OJYX1.SGD","LU1043141123.HKD","LU2213496289.HKD","SGXZ57979304.SGD","XLV","IHE","BK4550","PJP","IE00BFXG1179.USD","IYH","BK4139","JDOC","LU2750360641.GBP","VHT","TRUH","URGN","LU0122379950.USD","LU1914381329.SGD","LU2430703178.SGD","LU2468319806.SGD","LU1196500208.SGD","BK4532","LU1551013342.USD","GDOC","IXJ","MEDX","LU0203347892.USD","SG9999002224.SGD","LU0203345920.USD","LU2756315664.SGD","IE000M9KFDE8.USD","IE00B7SZLL34.SGD","FTXH","LU0289739699.SGD","LU1280957306.USD","RXL","SG9999002232.USD","LU2403377893.USD","IE000SO60NU8.SGD","SGXZ80539844.SGD","LU1291159041.SGD","TYRA","JNJ"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664333166","title":"UroGen Grants Inducement RSUs to 19 New Employees Covering up to 117,100 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=2664333166","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664333166?lang=en_us&edition=fundamental","pubTime":"2026-09-04 20:01","pubTimestamp":1788523283,"startTime":"0","endTime":"0","summary":"UroGen grants inducement RSUs to 19 new employees covering up to 117,100 sharesUroGen Pharma granted inducement restricted stock units to 19 new employees under its 2019 Inducement Plan.Up to 117,100 ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260904:nNDL3nNKgJ:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","IE00BGHQF748.EUR","IE00BQXX3C00.GBP","IE00BQXX3D17.EUR","IE00B64PRP62.GBP","SG9999014005.SGD","BCDF","SG9999014039.USD","IE00B3QW5Z07.USD","SG9999014013.SGD","SG9999014021.USD","LU2095319765.USD","IE00BN0W2T93.GBP","LU2210149790.SGD","LU0314104364.USD","NDAQ","BK4112","BK4585","IE00BN0W2V16.EUR","BK4139","IE00BKPKM429.USD","IE00BN0W2W23.USD","URGN","IE00BQXX3F31.USD","LU2210150020.SGD"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.urogen.com","stockEarnings":[{"period":"1week","weight":-0.1484},{"period":"1month","weight":-0.3282},{"period":"3month","weight":-0.3697},{"period":"6month","weight":-0.0224},{"period":"1year","weight":0.4508},{"period":"ytd","weight":0.2272}],"compareEarnings":[{"period":"1week","weight":-0.0071},{"period":"1month","weight":-0.0104},{"period":"3month","weight":-0.0023},{"period":"6month","weight":0.0396},{"period":"1year","weight":0.1356},{"period":"ytd","weight":0.1245}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution. The company's lead product candidate is UGN-102 for the treatment of several forms of non-muscle invasive urothelial cancer that include low-grade upper tract urothelial cancer and low-grade intermediate risk non-muscle invasive bladder cancer (NMIBC). It is also developing UGN-301 for the treatment of high-grade NMIBC. The company has license agreement with Agenus Inc. to develop, make, use, sell, import, and commercialize products of Agenus for the treatment of cancers of the urinary tract via intravesical delivery; strategic research collaboration agreement with MD Anderson focusing on the sequential use of UGN-201 and UGN-301 for the treatment of NMIBC; and licensing and supply agreement with medac Gesellschaft für klinische Spezialpräparate m.b.H. to develop UGN-103 in low-grade intermediate risk NMIBC and UGN-104 in low-grade upper tract urothelial carcinoma. UroGen Pharma Ltd. was incorporated in 2004 and is based in Princeton, New Jersey.","yearOnYearQuotes":[{"month":1,"riseRate":0.555556,"avgChangeRate":0.032111},{"month":2,"riseRate":0.333333,"avgChangeRate":-0.034111},{"month":3,"riseRate":0.333333,"avgChangeRate":-0.028291},{"month":4,"riseRate":0.555556,"avgChangeRate":0.07867},{"month":5,"riseRate":0.333333,"avgChangeRate":-0.100215},{"month":6,"riseRate":0.8,"avgChangeRate":0.326011},{"month":7,"riseRate":0.5,"avgChangeRate":0.11842},{"month":8,"riseRate":0.6,"avgChangeRate":0.040092},{"month":9,"riseRate":0.3,"avgChangeRate":-0.047593},{"month":10,"riseRate":0.5,"avgChangeRate":0.001251},{"month":11,"riseRate":0.6,"avgChangeRate":0.074503},{"month":12,"riseRate":0.333333,"avgChangeRate":-0.074086}],"exchange":"NASDAQ","name":"Urogen Pharma Ltd.","nameEN":"Urogen Pharma Ltd."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.1","shortVersion":"4.52.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Urogen Pharma Ltd.(URGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Urogen Pharma Ltd.(URGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Urogen Pharma Ltd.,URGN,Urogen Pharma Ltd.股票,Urogen Pharma Ltd.股票老虎,Urogen Pharma Ltd.股票老虎国际,Urogen Pharma Ltd.行情,Urogen Pharma Ltd.股票行情,Urogen Pharma Ltd.股价,Urogen Pharma Ltd.股市,Urogen Pharma Ltd.股票价格,Urogen Pharma Ltd.股票交易,Urogen Pharma Ltd.股票购买,Urogen Pharma Ltd.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Urogen Pharma Ltd.(URGN),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Urogen Pharma Ltd.(URGN) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction